Publication:
Omalizumab versus cyclosporin-A for the treatment of chronic spontaneous urticaria: can we define better-responding endotypes?

Placeholder

Organizational Units

Program

Authors

Authors

Kocaturk E.
BÜLBÜL BAŞKAN E.
SU KÜÇÜK Ö.
Ozdemir M.
Ornek S.
Can P. K.
Hasal E.
ENGİN B.
Atakan N.
ALPSOY E.

Advisor

Date

2022-09-01

Language

Type

Article

Publisher

Journal Title

Journal ISSN

Volume Title

Abstract

Background: Chronic Spontaneous Urticaria (CSU) is characterized by recurrent wheals and/or angioedema for longer than 6-weeks. Guidelines recommend Omalizumab (Oma) as first-line and Cyclosporine-A (Cs-A) as second-line treatment in antihistamine resistant CSU. This step-wise algorithm might be time-consuming and costly.

Description

Source:

Keywords:

Keywords

Tıp, Dahili Tıp Bilimleri, Dermatoloji, Sağlık Bilimleri, Medicine, Internal Medicine Sciences, Dermatology, Health Sciences, DERMATOLOJİ, Klinik Tıp, Klinik Tıp (MED), DERMATOLOGY, CLINICAL MEDICINE, Clinical Medicine (MED), Biomarker, Chronic urticaria, Cyclosporine, Omalizumab, BIOMARKERS

Citation

Kocaturk E., BÜLBÜL BAŞKAN E., SU KÜÇÜK Ö., Ozdemir M., Ornek S., Can P. K., Hasal E., ENGİN B., Atakan N., ALPSOY E., "Omalizumab versus cyclosporin-A for the treatment of chronic spontaneous urticaria: can we define better-responding endotypes?", ANAIS BRASILEIROS DE DERMATOLOGIA, cilt.97, sa.5, ss.592-600, 2022

URI

https://hdl.handle.net/20.500.12645/34604

Collections

Yayınlar - Eserler

Endorsement

Review

Supplemented By

Referenced By

0

Views

0

Downloads

View PlumX Details


Sustainable Development Goals